Mon, January 7, 2019
Fri, January 4, 2019
Thu, January 3, 2019
Wed, January 2, 2019
Mon, December 31, 2018
Fri, December 28, 2018
Thu, December 27, 2018
Wed, December 26, 2018
Fri, December 21, 2018
Thu, December 20, 2018
Wed, December 19, 2018
Tue, December 18, 2018
Mon, December 17, 2018
Fri, December 14, 2018
Thu, December 13, 2018
Wed, December 12, 2018
Tue, December 11, 2018
Mon, December 10, 2018
Fri, December 7, 2018
Thu, December 6, 2018
Wed, December 5, 2018
Tue, December 4, 2018
Mon, December 3, 2018

Christopher Marai Maintained (SNDX) at Strong Buy with Decreased Target to $12 on, Dec 17th, 2018


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-12-on-dec-17th-2018.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI


Christopher Marai of Nomura, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Decreased Target from $22 to $12 on, Dec 17th, 2018.

Christopher has made no other calls on SNDX in the last 4 months.



There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebowitz of "Morgan Stanley" Downgraded from Buy to Hold on, Monday, October 29th, 2018


This is the rating of the analyst that currently disagrees with Christopher


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $12 on, Thursday, October 11th, 2018

Publication Contributing Sources